ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1104

A Genome-Wide Association Study of Gout in People of European Ancestry

Tony R. Merriman1, Murray Cadzow1, Marilyn E. Merriman1, Amanda Phipps-Green1, Ruth Topless1, Abhishek Abhishek2, Mariano Andrés3, Linda A. Bradbury4, Russell Buchanan5, Katie Cremin6, Erika De Guzman6, Janak de Zoysa7, Michael Doherty8, Catherine Hill9, Tom W.J. Huizinga10, Tim Jansen11, M. Janssen12, Leo .A.B. Joosten13, Fina Kurreeman14, Susan Lester15, Frederic Liote16, Donia Macartney-Coxson17, Hirotaka Matsuo18, Geraldine M. McCarthy19, Sally McCormick20, Rinki Murphy21, Karel Pavelka22, Fernando Perez-Ruiz23, Juan Puig24, Timothy RDJ Radstake25, Philip Riches26, Maureen Rischmueller27, Edward Roddy28, Malcolm Smith29, Eli A. Stahl30, Blanka Stiburkova31, Richard Stubbs32, Anne-Kathrin Tausche33, Rosa Torres34, Rob Walker1, Ken Yamamoto35, Matthew A. Brown6, Hyon K. Choi36, Nicola Dalbeth21, Jeffrey N. Miner37, Alexander So38, Lisa K. Stamp39 and Tanya Major40, 1University of Otago, Dunedin, New Zealand, 2Devision of Rheumatology, University of Nottingham, NG5 1PB, England, 3Reumatología, Hospital General Universitario Alicante, Alicante, Spain, 4Queensland University of Technology, Brisbane, Australia, 5University of Melbourne, Melbourne, Australia, 6Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia, Brisbane, Australia, 7Waitemata District Health Board, Auckland, New Zealand, 8Academic Rheumatology, University of Nottingham, Nottingham, Great Britain, 9Medicine, The University of Adelaide, Adelaide, Australia, 10Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 11VieCuri Medical Center, Venlo, Netherlands, 12Department of Rheumatology, Rijnstate Hospital Arnhem, Arnhem, Netherlands, 13Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, 14Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, Leiden, Netherlands, 15Rheumatology, Queen Elizabeth Hospital, Woodville South, Australia, 16University Paris Diderot, Paris, France, 17Institute if Environmental and Scientific Reseacrh, Wellington, New Zealand, 18Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Tokorozawa, Japan, 19Div of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland, 20Department of Biochemistry, University of Otago, Dunedin, New Zealand, 21University of Auckland, Auckland, New Zealand, 22Institute of Rheumatology, Prague, Czech Republic, 23BioCruces Health Research Institute, Barakaldo, Spain, 24Hospital Universitario La Paz, Madrid, Spain, 25Rheumatic Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 26University of Edinburgh, Edinburgh, United Kingdom, 27Rheumatology, The Queen Elizabeth Hospital, South Australia, Adelaide, Australia, 28Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom, 29Flinders Medical Centre and Repatriation Hospital, Adelaide, Australia, 30Divisions of Rheumatology and Genetics, Brigham and Women's Hospital, Boston, MA, 31Institute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University, Prague, Czech Republic, 32P3 Research Limited, Wellington, New Zealand, 33Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, 34La Paz University Hospital, Madrid, Spain, 35Department of Medical Chemistry, Kurume University School of Medicine, Kurume, Japan, 36Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 37Discovery Biology, Ardea Biosciences, Inc., San Diego, CA, 38Rheumatology, CHUV, Univ of Lausanne, Lausanne, Switzerland, 39University of Otago, Christchurch, New Zealand, 40Biochemistry, University of Otago, Dunedin, New Zealand

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: genetics, genome and gout

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Metabolic and Crystal Arthropathies Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

A genome-wide association study of gout in people of European ancestry

Background/Purpose: Genome wide association studies (GWAS) have provided considerable insight into the molecular control of urate levels. However, less is known about the progression from asymptomatic hyperuricemia to gout. Our aim was to conduct a GWAS for gout in people of European ancestry using the largest number of cases of gout to date.

Methods: This GWAS (7,431 cases and 105,631 controls) was comprised of three data sets: a mixed New Zealand (NZ), Eurogout, and Ardea Biosciences group (3,961 cases; 1,547 controls; genotyped using the Illumina CoreExome v24 array, 547,644 markers), a composite set from the Health Professionals Follow-Up (HPFS) and NursesÕ Health Studies (NHS) (1,038 cases; 1,095 controls; genotyped using the Illumina OmniExpress v12 array, 730,525 markers), and UK Biobank (2,432 cases; 102,989 controls; genotyped using an Affymetrix Axiom array, 820,967 markers). The UK Biobank genotypes were imputed to ~73.3M SNPs. Neither the NZ/Eurogout/Ardea nor NHS/HPFS genotype sets were imputed. Markers found within all three data sets (234,062) were identified and associated with gout (adjusted for sex and age), within each data set separately, using PLINK v1.9. An inverse-variance weighted meta-analysis of the results was then performed using the meta v4.4 package within R v3.2.3. The overall genome inflation factor was 0.90.

Results: There were nine loci with experiment-wide significance (0.05/234,062; P < 2×10-7) for association with gout: ABCG2 (OR=1.77), SLC2A9 (OR=1.69), GCKR (OR=1.24), MLXIPL (OR=1.18), SLC17A1-A4 (OR=1.22), SLC16A9 (OR=1.18), SLC22A12 (OR=1.16), PDZK1 (OR=1.16), TRIM46 (OR=1.15). All nine of these loci have been previously associated with serum urate levels in genome-wide studies with the urate-increasing alleles also associated with increased risk of gout in this study.  

Conclusion: Our data emphasize the central importance of genetic involvement in serum urate levels, compared to the genetic involvement in MSU crystal formation, or the innate immune response, in determining gout.


Disclosure: T. R. Merriman, Ardea Biosciences, 2; M. Cadzow, None; M. E. Merriman, Ardea Biosciences, Inc, 2; A. Phipps-Green, None; R. Topless, None; A. Abhishek, AstraZeneca, 7; M. Andrés, None; L. A. Bradbury, None; R. Buchanan, None; K. Cremin, None; E. D. Guzman, None; J. de Zoysa, None; M. Doherty, None; C. Hill, None; T. W. J. Huizinga, Reasearch grants from Arthritis Foundation, ZonMW and European Union, 2,Tom WJ Huizinga/the department of rheumatology LUMC has received lecture fees/consultancy fees from Bristol Myers Squibb, Janssen, Pfizer, Roche, Sanofi-Aventis, Crescendo Bioscience,, Boeringher, Epirus and Eli Lilly, 5; T. Jansen, None; M. Janssen, None; L. A. B. Joosten, None; F. Kurreeman, None; S. Lester, None; F. Liote, None; D. Macartney-Coxson, None; H. Matsuo, None; G. M. McCarthy, None; S. McCormick, None; R. Murphy, None; K. Pavelka, None; F. Perez-Ruiz, Asociacion de reumatologos de Cruces, 2,Grünenthal, 5,Grünenthal, 8,Menarini, 5,Menarini, 8; J. Puig, None; T. R. Radstake, None; P. Riches, None; M. Rischmueller, None; E. Roddy, None; M. Smith, None; E. A. Stahl, None; B. Stiburkova, None; R. Stubbs, None; A. K. Tausche, None; R. Torres, None; R. Walker, None; K. Yamamoto, None; M. A. Brown, None; H. K. Choi, None; N. Dalbeth, Takeda, AstraZeneca, Abbvie, 9; J. N. Miner, Ardea biosciences, 3; A. So, None; L. K. Stamp, Amgen, 8; T. Major, None.

To cite this abstract in AMA style:

Merriman TR, Cadzow M, Merriman ME, Phipps-Green A, Topless R, Abhishek A, Andrés M, Bradbury LA, Buchanan R, Cremin K, Guzman ED, de Zoysa J, Doherty M, Hill C, Huizinga TWJ, Jansen T, Janssen M, Joosten LAB, Kurreeman F, Lester S, Liote F, Macartney-Coxson D, Matsuo H, McCarthy GM, McCormick S, Murphy R, Pavelka K, Perez-Ruiz F, Puig J, Radstake TR, Riches P, Rischmueller M, Roddy E, Smith M, Stahl EA, Stiburkova B, Stubbs R, Tausche AK, Torres R, Walker R, Yamamoto K, Brown MA, Choi HK, Dalbeth N, Miner JN, So A, Stamp LK, Major T. A Genome-Wide Association Study of Gout in People of European Ancestry [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/a-genome-wide-association-study-of-gout-in-people-of-european-ancestry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-genome-wide-association-study-of-gout-in-people-of-european-ancestry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology